DexCom (DXCM) traded lower on April 24, 2026, extending a run of choppy trading as the market remains focused on competitive pressure in continuous glucose monitoring (CGM) and the company’s near-term growth cadence. There was no single new company announcement driving the move, leaving the stock to trade primarily on positioning and the existing narrative around 2026 expectations.

A key bearish framework on DexCom has been share and pricing pressure as Abbott pushes deeper into DexCom’s historical strongholds. That competitive concern has shown up in analyst actions in recent months, with commentary highlighting Abbott’s scale in CGM and potential next-generation product threats over the 2026–2027 window. (investing.com)

The next major scheduled catalyst is DexCom’s Q1 2026 earnings report on April 30, 2026 (after the close), which can reset expectations around U.S. growth, international momentum, and margins. Investors are also watching reimbursement dynamics, including the pace and timing of CMS-related developments that could expand coverage in Type 2 patients not using insulin—an area that has been a source of volatility when timelines appear uncertain. (benzinga.com)

Into earnings, traders will likely key on (1) any update to full-year 2026 guidance, (2) U.S. patient growth and channel commentary, (3) product mix and sensor economics, and (4) any clarity on reimbursement/coverage expansion that could widen the addressable market. DexCom has recently reiterated its 2026 framework in its latest full-year results update, keeping attention on execution against that plan as the stock reacts to each incremental data point. (investors.dexcom.com)